See how Agilent's AdvanceBio SEC columns eliminate slow separations, poor resolution, and other roadblocks to successful mAb analysis. The new columns represent a critical advance in size-exclusion chromatography, a key technology used to quantify aggregation in biotherapeutics such as monoclonal antibodies. This is a vital factor in developing and producing safe, effective biologics. Agilent AdvanceBio SEC columns deliver reproducible results — column to column, batch to batch, and lab to lab. Designed from the ground up by Agilent polymer engineers and synthetic chemists, these innovative columns put a stop to uncertainty with the high resolution, consistency, and flow rates that monoclonal antibodies separations demand.